A large study of children has uncovered evidence that behavioral problems in children who snore may be associated with changes in the structure of their brain’s frontal lobe. The findings support the early evaluation of children with habitual snoring (sno ...
Although extremely rare, Parkinson’s-like symptoms have occurred in a few people with COVID-19. This phenomenon has researchers investigating whether there is a link between SARS-CoV-2 and Parkinson’s disease. Since the start of the COVID-19 pandemic, sc ...
A new SARS-CoV-2 spike enhances replication. During the evolution of SARS-CoV-2 in humans a D614G substitution in the spike (S) protein emerged and became the predominant circulating variant (S-614G) of the COVID-19 pandemic. However, whether the in ...
In the first ever placebo-controlled phase 3 trial in patients with relapsed mesothelioma, immunotherapy with nivolumab (Opdivo) significantly improved both overall survival (OS) and progression-free survival (PFS). The CONFIRM trial involv ...
Scientists are starting to work out how the gut microbiome can affect brain health. That might lead to better and easier treatments for brain diseases In 2006, soon after she launched her own laboratory, neuroscientist Jane Foster discovered ...
A study has described genetic changes in patients with the most common form of hereditary kidney disease that affects an estimated 12.5 million people worldwide. The research, which focused on Polycystic Kidney Disease (PKD) in Ireland, provides ins ...
A growing number of Americans have chronic kidney disease, but most remain unaware of it, hampering efforts to prevent irreversible kidney failure requiring dialysis or a transplant, according to a study funded by the National Institutes of Health a ...
This February we are raising awareness for American Heart Month and discussing prevention steps for heart diseases. Heart disease is the leading cause of death and every 36 seconds someone in the United States dies from a heart condition. This month ...
A novel drug, tafasitamab-cxix (Monjuvi, MorphoSys US Inc), has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The product is a ...